In India, it is estimated that up to 1.5% of the population has a hepatitis C infection, with certain areas in the Punjab, North East and tribal areas considered possible “hepatitis C virus hotspots”. With a global burden of 130-150 million people, hepatitis C, along with hepatitis B, are among the leading causes of liver cancer and pose a significant health challenge.
The standard of care for hepatitis C has changed over the years. Initially, it was only injectable interferon. Later, combinations of injectable interferon or pegylated interferon with ribavirin and protease inhibitors were introduced. More recently, the World Health Organization has recommended that newer oral agents called direct antiviral agents (DAA) be included for all patients with hepatitis C. DAAs have been found to be better tolerated, safer, need to be taken for a shorter time and are more effective.
Dr. Samir Shah, Head, Department of Hepatology, Institute of Liver Diseases, HPB Surgery and Transplant, Global Hospitals,Mumbai recently presented the results from a 14-centre study across India where a DAA, sofosbuvir, was used in an interferon-free combination with ribavirin, for 117 treatment-naïve patients with chronic hepatitis C infections. “We found that this regimen was more effective in our Indian patients than the reports from the West,” he said.
New Delhi, July 27 (IANS) Despite the cost of drugs coming down and dramatic advances in the treatment of Hepatitis B and Hepatitis C, getting rid of both types of the disease remains a huge challenge primarily due to lack of awareness and unsafe injection practices, experts have rued.
Hepatitis B is 50-100 times more infectious than HIV and Hepatitis C is 10 times more infectious than the virus that can cause AIDS. Yet, while people are by and large aware of HIV, there is little awareness about Hepatitis, health experts have lamented.
“In India, Hepatitis is a matter of concern because three to six billion injections are given each year, of which two-thirds are unsafely administered. This makes a large part of the population vulnerable to viruses transmitted through the blood,” Siddharth Srivastava, Associate Professor, GB Pant Hospital here told IANS.
NEW DELHI: Drug firm Mylan NV has launched generic Harvoni tablets, used to treat Hepatitis C, under the brand name ‘MyHep LVIR’ in India.
Mylan Pharmaceuticals Pvt Ltd, a subsidiary of the company has launched generic Harvoni in the country, Mylan NV said in a statement.
“Mylan recognises the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus,” Mylan President Rajiv Malik